Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster
The novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented....
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/12/1996 |
| _version_ | 1797455057403248640 |
|---|---|
| author | Zhenye Niu Xueqi Li Yang Gao Lichun Wang Shengtao Fan Xingli Xu Guorun Jiang Pingfang Cui Dandan Li Yun Liao Li Yu Heng Zhao Ying Zhang Qihan Li |
| author_facet | Zhenye Niu Xueqi Li Yang Gao Lichun Wang Shengtao Fan Xingli Xu Guorun Jiang Pingfang Cui Dandan Li Yun Liao Li Yu Heng Zhao Ying Zhang Qihan Li |
| author_sort | Zhenye Niu |
| collection | DOAJ |
| description | The novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented. Whether multiple antigen matches are necessary to induce a better immune response remains unclear. To address this question, this study tested the immunogenicity and protective effects of a SARS-CoV-2 recombinant S and N peptide vaccine in the Syrian golden hamster model. This experiment was based on two immunization methods: intradermal and intramuscular administration. Immunized hamsters were challenged with live SARS-CoV-2 14 days after booster immunization. Clinical symptoms were observed daily, and the antibody titer and viral load in each tissue were detected. The results showed that immunization of golden hamsters with the SARS-CoV-2 structural protein S alone or in combination with the N protein through different routes induced antibody responses, whereas immunization with the N protein alone did not. However, although the immunized hamsters exhibited partial alleviation of clinical symptoms when challenged with the virus, neither vaccine effectively inhibited the proliferation and replication of the challenging virus. In addition, the pathological damage in the immunized hamsters was similar to that in the control hamsters. Interestingly, the neutralizing antibody levels of all groups including immunized and nonimmunized animals increased significantly after viral challenge. In conclusion, the immune response induced by the experimental S and N polypeptide vaccines had no significant ability to prevent viral infection and pathogenicity in golden hamsters. |
| first_indexed | 2024-03-09T15:46:06Z |
| format | Article |
| id | doaj.art-c3a90b9f72c546359caf983942a9e4eb |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T15:46:06Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-c3a90b9f72c546359caf983942a9e4eb2023-11-24T18:30:51ZengMDPI AGVaccines2076-393X2022-11-011012199610.3390/vaccines10121996Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden HamsterZhenye Niu0Xueqi Li1Yang Gao2Lichun Wang3Shengtao Fan4Xingli Xu5Guorun Jiang6Pingfang Cui7Dandan Li8Yun Liao9Li Yu10Heng Zhao11Ying Zhang12Qihan Li13Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming 650118, ChinaThe novel coronavirus (SARS-CoV-2) epidemic continues to be a global public crisis affecting human health. Many research groups are developing different types of vaccines to suppress the spread of SARS-CoV-2, and some vaccines have entered phase III clinical trials and have been rapidly implemented. Whether multiple antigen matches are necessary to induce a better immune response remains unclear. To address this question, this study tested the immunogenicity and protective effects of a SARS-CoV-2 recombinant S and N peptide vaccine in the Syrian golden hamster model. This experiment was based on two immunization methods: intradermal and intramuscular administration. Immunized hamsters were challenged with live SARS-CoV-2 14 days after booster immunization. Clinical symptoms were observed daily, and the antibody titer and viral load in each tissue were detected. The results showed that immunization of golden hamsters with the SARS-CoV-2 structural protein S alone or in combination with the N protein through different routes induced antibody responses, whereas immunization with the N protein alone did not. However, although the immunized hamsters exhibited partial alleviation of clinical symptoms when challenged with the virus, neither vaccine effectively inhibited the proliferation and replication of the challenging virus. In addition, the pathological damage in the immunized hamsters was similar to that in the control hamsters. Interestingly, the neutralizing antibody levels of all groups including immunized and nonimmunized animals increased significantly after viral challenge. In conclusion, the immune response induced by the experimental S and N polypeptide vaccines had no significant ability to prevent viral infection and pathogenicity in golden hamsters.https://www.mdpi.com/2076-393X/10/12/1996spike proteinnucleocapsid proteinpolypeptide vaccineSyrian golden hamster |
| spellingShingle | Zhenye Niu Xueqi Li Yang Gao Lichun Wang Shengtao Fan Xingli Xu Guorun Jiang Pingfang Cui Dandan Li Yun Liao Li Yu Heng Zhao Ying Zhang Qihan Li Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster Vaccines spike protein nucleocapsid protein polypeptide vaccine Syrian golden hamster |
| title | Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster |
| title_full | Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster |
| title_fullStr | Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster |
| title_full_unstemmed | Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster |
| title_short | Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster |
| title_sort | evaluation of immunogenicity and clinical protection of sars cov 2 s1 and n antigens in syrian golden hamster |
| topic | spike protein nucleocapsid protein polypeptide vaccine Syrian golden hamster |
| url | https://www.mdpi.com/2076-393X/10/12/1996 |
| work_keys_str_mv | AT zhenyeniu evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT xueqili evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT yanggao evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT lichunwang evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT shengtaofan evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT xinglixu evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT guorunjiang evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT pingfangcui evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT dandanli evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT yunliao evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT liyu evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT hengzhao evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT yingzhang evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster AT qihanli evaluationofimmunogenicityandclinicalprotectionofsarscov2s1andnantigensinsyriangoldenhamster |